Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...
Medscape7h
Isatuximab Approved First-Line for Transplant-Ineligible MM
In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...
Hosted on MSN21h
Moving mountains: Boulder woman's battle against multiple myeloma during Blood Cancer Awareness Month
A Boulder woman is opening up about her fight with multiple myeloma during Blood Cancer Awareness Month. She went from being ...